Phase 4 N=18 Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
AIDS
Primary: Standing and Supine Systolic and Diastolic Blood Pressure (BP) — 118.36; 119.47; 68.06; 69.99 mm Hg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=27 Effects of Nebivolol Versus Carvedilol on Cardiopulmonary Function at High Altitude in Healthy Subjects.
Hypoxia · Altitude · Heart Failure
Primary: Peak Exercise Oxygen Consumption — 33.9; 37.6; 38.0; 33.9 ml/Kg/min — p=0.01
Phase 4 N=33 A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects
Healthy
Primary: Change From Baseline in Skin Health, Visual Skin Score (VSS) at 14 Days — 0.1; 0.4 units on a scale
Phase 4 N=112 DisCoVisc Versus DuoVisc, Healon5 and AmVisc Plus
Cataract
Primary: Corneal Endothelial Cell Loss — 1.51; 1.18; 4.72; 6.30 Percent Change
Phase 4 N=34 A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease
Mucopolysaccharidosis I · Hurler's Syndrome · Hurler-Scheie Syndrome
Primary: Percent Change From Baseline to Week 26 in Urinary Glycosaminoglycan (GAG) Level — -57.57; -66.63; -66.15; -62.66 Percentage of Change in GAG Level
Phase 4 N=278 Open Label Comparative Study On Celecoxib Efficacy And Safety Vs Non-Selective NSAID In Acute Pain Due To Ankle Sprain
Ankle Sprain
Primary: Change From Baseline at Day 3 in Pain Visual Analog Scale (VAS) - Per Protocol Population — -44.88; -40.76 scores on a scale
Phase 4 N=467 Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
Appendicitis · Cholecystitis · Cross Infection
Primary: Number of Clinically Evaluable Patients With Clinical Response of Cure at Test-of-Cure (TOC) Visit. — 133; 139 participants — p=0.009
Phase 4 N=60 The Effects of Formula Diet on Body Weight, Body Composition, and Biomarkers for Disease Compared to a Standard Diet
Body Weight Changes
Primary: Body Weight Loss (kg and Percent) at Months 3 and 6
Phase 4 N=57 Effects of Divalproex Sodium on Food Intake, Energy Expenditure, and Posture Allocation
Healthy
Primary: Change in Food Intake. — -51; -90 kcal
Phase 4 N=526 ADVANCE CRT - D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy
Tachycardia, Ventricular · Ventricular Fibrillation
Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy (Burst, 8 Pulses, 88 %, 1 Sequence) to Terminate All Types of Ventricular Tachycardia. — 64.7; 68.2 Percent of VT…
Phase 4 N=117 A Study for Patients With Diabetes Mellitus (IOPA)
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Glycosylated Hemoglobin (HbA1c) Value at 12 Week Endpoint — 7.91; 7.96 percent of glycosylated hemoglobin — p=0.497
Phase 4 N=66 A Study to Evaluate Raptiva in Subjects With Chronic Moderate or Worse Plaque Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent
Psoriasis
Primary: Proportion of Subjects With a Physician's Global Assessment (PGA) Rating of Clear (0), Almost Clear (1), or Mild (2) — 34.8 percentage
Phase 4 N=18 A Study To Evaluate An Interaction Between Maraviroc And Raltegravir In Healthy Subjects
Healthy
Primary: Maraviroc Pharmacokinetic (PK) Parameter: Area Under the Plasma Concentration-time Profile Over the Dosing Interval (AUCτ) — 2551.9; 2971.6 ng.hr/mL
Phase 4 N=113 A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: The Percentage of Patients Achieving HbA1c <=7% at Week 24 With no Gain in Body Weight From Baseline and no Incidence of Severe Hypoglycemia — 30.4; 10.7 Percent…
Phase 4 N=120 Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
Influenza
Primary: Number of Participants Reporting Solicited Injection Site and Solicited Systemic Reactions After Fluzone® Vaccination — 40; 10; 4; 6 Participants